Pfizer (NYSE:PFE) reported Phase 2 results showing that investigational tilrekimig achieved its primary endpoint by producing statistically significant increases in EASI-75 responses compared with placebo at Week 16 in adults with moderate-to-severe atopic dermatitis.
Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) received authorization from Health Canada for their Omicron XFG-adapted COVID-19 vaccine.
Pfizer (NYSE:PFE) announced today that its Chief Financial Officer, Dave Denton, will depart the company on August 15, 2026, to accept a new position within the consumer goods industry.
Pfizer (NYSE:PFE) disclosed preliminary data from its Phase 2 clinical trial evaluating PF-07872412, an investigational 25-valent pneumococcal conjugate vaccine candidate designed for pediatric use.
